α-Synuclein-IN-25

α-Synuclein-IN-25 (3eb) (30 μM; 72 h) potently inhibits α-Synuclein aggregation in a cell-free system with an AIR of 90.9%^[1].
α-Synuclein-IN-25 (0-100 μM) inhibits α-Synuclein aggregation in a dose-dependent manner in a cell-free system, with an IC₅₀ of 3.0 μM^[1].
α-Synuclein-IN-25 (30 μM; 72 h) stabilizes the native random coil conformation of α-Synuclein and inhibits its conversion to β-sheet-rich aggregates in a cell-free system^[1].
α-Synuclein-IN-25 (30 μM; up to 96 h) inhibits α-Synuclein aggregation throughout the entire process in a cell-free system, reducing the fibril growth rate (K_app = 0.12 h⁻¹) by targeting oligomeric nuclei formation in the lag phase^[1].
α-Synuclein-IN-25 (30 μM; 88 h) reduces the formation of large, interconnected α-Synuclein fibrils, resulting in small, sparse aggregates in a cell-free system^[1].
α-Synuclein-IN-25 binds to the aggregation-prone 58-79 fragment of α-Synuclein with a binding energy of -9.80 kcal/mol via multiple intermolecular interactions^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.